Browse diseases

…dictive performance of ML in classifying CTRCD risk among HER2+ breast cancer patients.Methods A retrospective service evaluation included 20…

…% of women stop endocrine therapy for hormone-receptor-positive breast cancer within the first 5 years of prescribed treatment because of sid…

…esigned studies. To focus on the metastatic setting relevant to oligometastatic disease, trials referring to early-stage (stage I–II) or locally advanc…

…ze immunotype-associated cellular landscapes in triple-negative breast cancer (TNBC) and identify features associated with clinical outcomes.…

…Introduction Postoperative depressive symptoms are common after breast cancer surgery and can adversely affect recovery and quality of life. …

…tic pathways and outcomes. The increased risk of advanced-stage breast cancer is of particular note. Improved support to access and navigate …

…Introduction Breast cancer poses substantial public health and economic burdens worldwide,…

…Breast cancer is the most common invasive malignancy among women and represen…

…Breast cancer brain metastasis (BCBrM) remains one of the most lethal manifes…

…ss and safety of abemaciclib in women diagnosed with metastatic breast cancer, hormone receptor-positive (HR+) and human epidermal growth fac…

…ortance Dose-dense (DD) chemotherapy has been incorporated into breast cancer management with the objective of enhancing therapeutic efficacy…

…icant strain on both Ukrainian and neighbouring health systems. Cancer incidence appeared lower due to delayed detection and migration…